Tumor-altered dendritic cell function: implications for anti-tumor immunity.
about
Functional Specialization of Skin Dendritic Cell Subsets in Regulating T Cell ResponsesModulation of APC Function and Anti-Tumor Immunity by Anti-Cancer DrugsDendritic cell vaccination, immune regulation, and clinical outcomes in ovarian cancerTumor-infiltrating dendritic cells in cancer pathogenesisTransforming growth factor-beta and matrix metalloproteinases: functional interactions in tumor stroma-infiltrating myeloid cellsDysregulation of TGFβ1 Activity in Cancer and Its Influence on the Quality of Anti-Tumor ImmunityThe Multifaceted Roles Neutrophils Play in the Tumor MicroenvironmentThe role of tumor/dendritic cell interactions in the regulation of anti-tumor immunity: the good, the bad, and the uglyDecreased intratumoral Foxp3 Tregs and increased dendritic cell density by neoadjuvant chemotherapy associated with favorable prognosis in advanced gastric cancerThe role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014Prognostic stromal gene signatures in breast cancer.The role of tumor-associated macrophages in breast carcinoma invasion and metastasis.PD-1 Blunts the Function of Ovarian Tumor-Infiltrating Dendritic Cells by Inactivating NF-κBImmune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy.IL-10 expression defines an immunosuppressive dendritic cell population induced by antitumor therapeutic vaccination.Oncolytic virus-mediated reversal of impaired tumor antigen presentation.Murine and Human Model Systems for the Study of Dendritic Cell Immunobiology.Microenvironment of tumor-draining lymph nodes: opportunities for liposome-based targeted therapy.Dendritic cell defects in the colorectal cancerImpact of VEGF gene polymorphisms in elderly cancer patients: clinical outcome and toxicity.The extent to which melanoma alters tissue-resident dendritic cell function correlates with tumorigenicity.A model system for the study of gene expression in the undergraduate laboratory.The microtubule-depolymerizing agent ansamitocin P3 programs dendritic cells toward enhanced anti-tumor immunity.Stromal contributions to the carcinogenic process.Norm- and hypo-fractionated radiotherapy is capable of activating human dendritic cells.Cancer chemotherapy agents target intratumoral dendritic cells to potentiate antitumor immunity.Tumor-derived α-fetoprotein impairs the differentiation and T cell stimulatory activity of human dendritic cells.Systems biological analyses reveal the hepatitis C virus (HCV)-specific regulation of hematopoietic development.Multifaceted Role of Neuropilins in the Immune System: Potential Targets for ImmunotherapyStrategies to Improve the Efficacy of Dendritic Cell-Based Immunotherapy for Melanoma.Use of antigen-primed dendritic cells for inducing antitumor immune responses in vitro in patients with non-small cell lung cancer.Expression of CD14, IL10, and Tolerogenic Signature in Dendritic Cells Inversely Correlate with Clinical and Immunologic Response to TARP Vaccination in Prostate Cancer Patients.Melanoma-derived factors alter the maturation and activation of differentiated tissue-resident dendritic cells.Vaccine immunotherapy with ARNAX induces tumor-specific memory T cells and durable anti-tumor immunity in mouse models.Immuno-Oncology: Emerging Targets and Combination Therapies
P2860
Q26777948-4CB0198E-2161-4C8A-8815-673F2C17A9EFQ26781522-1533F20B-B3A3-44E7-B0BC-F752D8856EF6Q26861293-F567ABAD-E7E0-4320-9F85-07756D494595Q26861633-5852715D-77EC-4147-85C8-07299DE80399Q26996742-1B9DB678-BEE7-40C1-B2D4-AB23543B3659Q28075996-3102AB3F-7217-4A14-8AD8-809489C5D0AFQ28241308-9C0B8BA7-6F5E-4487-B170-6A598C8B7527Q30413213-4DE0DD23-D63E-44EE-AB52-BA9FD5BDE2F3Q34121330-61F3FA73-CFBF-4FB6-BB8C-E4D4C681A838Q34402325-73959410-9A12-4075-8996-C72B3E079185Q35180291-E26361B8-15FE-420E-B9C2-F01AFE204317Q35919089-6C895703-57F6-4636-9FEB-DE0C937D7BD9Q36471523-450D3291-48B5-48EA-A9E7-EC356A80F47DQ37676065-44FC22DC-22BF-4985-9AAA-3FCC12ED1B04Q37709350-AE4DDF64-0DD3-4846-9968-19A928690C81Q38208315-833F503D-ADC7-4F5B-9DAF-BDE135994929Q38247413-A8B81D71-FCF4-4C78-A418-236EDEA440C7Q38266149-67067B06-2C99-4331-AB04-A3458A7C4226Q38284706-357DB147-FF3D-4E63-8F4D-5CEDCB6A8E98Q38307997-3B6E0029-AF79-4500-8719-2ECD96CD6086Q38563907-B351C978-692D-4AA1-BCBF-F2E12EE6CE24Q38792219-77AF2152-170C-499D-A465-33FAD1DC19E4Q38987399-D0882FD7-2D4D-472F-9B37-88A2903195D3Q38992680-E2CCE398-4471-48AD-95C0-B8BEA7FBCE78Q39025449-4CA921F6-16D5-4D35-973E-C781568F2528Q41545176-11547578-C69D-40D0-9511-B7132DEE26BDQ41874816-5A33661E-0E7F-4709-A5ED-4BAD3977577DQ41893128-DDF8C096-6E27-4FEA-B388-49BF6BB879DFQ42654195-52BBF0B2-428B-4304-9A7A-1B484689CB73Q47135720-340C0AA0-B08F-4365-B441-7E3E30E49CB8Q49334976-B739BA36-4F45-43EC-8CEC-399C717143ECQ51201669-0ACF0F93-74E0-43C9-A665-3E44A74206A9Q53493928-26FCEFC5-D33C-403A-8922-9B2B12DE260CQ55518179-31284647-6CFF-4A6B-8E90-6B0FE3BABEAFQ56889817-5E22C1A9-DAE4-444B-808E-B08DA9F1EA93
P2860
Tumor-altered dendritic cell function: implications for anti-tumor immunity.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Tumor-altered dendritic cell function: implications for anti-tumor immunity.
@en
type
label
Tumor-altered dendritic cell function: implications for anti-tumor immunity.
@en
prefLabel
Tumor-altered dendritic cell function: implications for anti-tumor immunity.
@en
P2860
P356
P1476
Tumor-altered dendritic cell function: implications for anti-tumor immunity.
@en
P2093
Kristian M Hargadon
P2860
P356
10.3389/FIMMU.2013.00192
P577
2013-07-11T00:00:00Z